Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1 Terminated
67 enrolled
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Phase 1 Terminated
25 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
Phase 1 Terminated
25 enrolled
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Phase 1 Terminated
17 enrolled
GVAX Plus Checkpoint Blockade in Neuroblastoma
Phase 1 Terminated
19 enrolled
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Phase 1 Terminated
5 enrolled 8 charts
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Phase 1 Terminated
21 enrolled
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
Phase 1 Terminated
6 enrolled
PANAMA
Phase 1 Terminated
60 enrolled 22 charts
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
PRIMO
Phase 1 Terminated
25 enrolled
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Phase 1 Terminated
6 enrolled
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Phase 1 Terminated
13 enrolled
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
Phase 1 Terminated
10 enrolled
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Phase 1 Terminated
17 enrolled
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Phase 1 Terminated
1 enrolled
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Phase 1 Terminated
21 enrolled
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Phase 1 Terminated
9 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Phase 1 Terminated
22 enrolled 14 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
5 enrolled
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
5 enrolled
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Phase 1 Terminated
6 enrolled
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Phase 1 Terminated
4 enrolled
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase 1 Terminated
6 enrolled
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
Phase 1 Terminated
15 enrolled
CheckMate 76U
Phase 1 Terminated
21 enrolled
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
Phase 1 Terminated
7 enrolled
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase 1 Terminated
41 enrolled 24 charts
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
Phase 1 Terminated
2 enrolled
Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
Phase 1 Terminated
10 enrolled
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Phase 1 Terminated
82 enrolled
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
15 enrolled
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Phase 1 Terminated
3 enrolled
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Phase 1 Terminated
2 enrolled
Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer
Phase 1 Terminated
14 enrolled
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Phase 1 Terminated
6 enrolled
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1 Terminated
36 enrolled 17 charts
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
Phase 1 Terminated
19 enrolled
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Phase 1 Terminated
22 enrolled
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
33 enrolled
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Phase 1 Terminated
16 enrolled
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Phase 1 Terminated
3 enrolled
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Phase 1 Terminated
3 enrolled
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Phase 1 Terminated
11 enrolled
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase 1 Terminated
1 enrolled 7 charts
NUANCE
Phase 1 Terminated
1 enrolled